Alemtuzumab and Treatment of Chronic Lymphocytic Leukemia and Its Immune-Related Disorders: One Player on Two Tables

Publisher： Karger

E-ISSN： 1421-9662|132|2|237-239

ISSN： 0001-5792

Source： Acta Haematologica, Vol.132, Iss.2, 2014-05, pp. : 237-239

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Successful Treatment of Refractory Guillain-Barré Syndrome with Alemtuzumab in a Patient with Chronic Lymphocytic Leukemia

By  

Acta Haematologica, Vol. 132, Iss. 2, 2014-05 ,pp. : 240-243

Karger

Access to resources Recommend Favorite

Ofatumumab for the treatment of chronic lymphocytic leukemia

By Robak Tadeusz  

Therapy, Vol. 6, Iss. 4, 2009-07 ,pp. : 577-587

Future Medicine

Access to resources Recommend Favorite

Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high‐risk relapsed/refractory chronic lymphocytic leukemia patients

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 1, 2015-01 ,pp. : 37-42

John Wiley & Sons Inc

Access to resources Recommend Favorite

Low‐dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long‐term outcome from a single center experience

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 11, 2015-11 ,pp. : 970-974

John Wiley & Sons Inc

Access to resources Recommend Favorite

New oral small molecules in the treatment of chronic lymphocytic leukemia

By  

CANCER, Vol. 121, Iss. 12, 2015-06 ,pp. : 1917-1926

John Wiley & Sons Inc

Access to resources Recommend Favorite